Dr. Aasma Shaukat and her research team plan to submit the updated SimpleScreen CRC test to the FDA for regulatory approval.

Overview Debates Related claims Topics Sources

Machine-learning models integrating early antibody signatures discriminated individuals who would later develop Crohn's disease or ulcerative colitis from healthy controls up to 10 years before diagnosis, with AUC values of 0.90 and 0.84, respectively.

Study co-author Dr. You Zhou stated that combining gut bacteria and digestive chemicals distinguished individuals with mild cognitive impairment from healthy people with high accuracy.

Researchers from Cardiff University and Imperial College London found that older adults with mild cognitive impairment displayed significantly elevated levels of Izemoplasmatales spp. bacteria and the chemical proline in fecal samples.

The study utilized machine learning algorithms to analyze fecal sample biomarkers to diagnose mild cognitive impairment and predict condition progression speed.

Researchers profiled antibody responses against approximately 357,000 antigens across 2,000 serum samples, identifying 123,980 unique antibodies and finding significantly lower antibody diversity in individuals who later developed Crohn's disease or ulcerative colitis.

Dr. Aasma Shaukat stated at the ACG Annual Scientific Meeting that researchers plan to develop future iterations beyond version two of SimpleScreen CRC to further increase sensitivity for advanced lesions.

Routine hemoglobin levels are a reliable clinical indicator of long-term dementia risk

The Dong-A University College of Medicine study found participants in the highest 20% of hemoglobin levels had a 7% higher risk of all-cause dementia and an 18% higher risk of vascular dementia.

Researchers categorized the 316,542 Korean participants into five equal groups based on hemoglobin levels to evaluate long-term dementia risk over a follow-up period of up to 15 years.

An exploratory analysis led by Wendy A. Woodward suggested that patients with low or absent pretreatment circulating tumor cells (CTCs) had improved progression-free survival with ablation, while those with elevated CTCs did not benefit.

Continuous biomarker monitoring does more harm than good for patient health

In a subgroup of 801 participants who took home HbA1c blood tests, the AI speech model correctly assigned higher risk scores to diabetic individuals 75% of the time.

The FDA advisory panel voted unanimously 10-0 that Grail Inc.'s Galleri test is safe, but voted narrowly 6-4 that there is reasonable assurance the test is effective.

The FDA advisory panel voted 7-2, with one member abstaining, that the probable benefits of Grail Inc.'s Galleri test outweigh its risks for patients meeting the proposed criteria.

The Precure Research initiative analyzes data on genes, proteins, metabolites, clinical records, wearable devices, and environmental exposures to detect early physiological changes.

The Grail-funded study published in Nature Medicine on September 22, 2026, found that more than half of the cancers caught by Grail's Galleri test were early stage, and most lacked routine screening.

Dr. Victor van Berkel of the University of Louisville stated his affirmative vote was hopeful rather than accurate, noting that the benefit of finding early-stage cancers with the test has not yet been proven.

Mayo Clinic initiated the Precure prospective study in January 2026, planning to enroll up to 100,000 participants to test biospecimens like blood, urine, saliva, and stool.

The FDA approved the Guardant360 Liquid CDx circulating tumor DNA assay to detect ESR1 mutations in breast cancer patients.

Patients most likely to benefit from PANXEON screening include individuals with inherited genetic risk, a family history of pancreatic cancer, pancreatic cysts, or chronic pancreatitis.